Clarivate Plc Stock Price, News & Analysis

Clarivate Plc (NYSE: CLVT) announced that Jerre Stead, Executive Chairman and CEO, and Richard Hanks, CFO, will present at the BofA Securities 2021 Information Services Conference on March 18, 2021, at 3:35 PM Eastern Time. A live webcast of the presentation will be accessible on the Investor Relations section of Clarivate's website, with a replay available for 30 days post-event. Clarivate aims to accelerate innovation by providing actionable information and insights to help clients navigate complex challenges.

Clarivate Plc (NYSE:CLVT) released its annual 'Drugs to Watch' list, spotlighting potential blockbuster drugs that could exceed $1 billion in sales by 2025. Highlighted drugs include Aducanumab for Alzheimer's, which could revolutionize treatment; Bimekizumab for psoriasis, offering improved efficacy; Relugolix, an oral treatment for prostate cancer; and Vericiguat for heart failure. The report reflects the accelerated pace of biopharma innovation, driven by insights from COVID-19 developments, faster trials, and increased investment in research and development.

Clarivate Plc (NYSE: CLVT) has launched the Web of Science™ Author Impact Beamplots, an innovative tool that visualizes a researcher's publication and citation impact comprehensively. Unlike traditional metrics, beamplots provide a normalized citation count, offering deeper insights into researchers' performance over time. This tool aims to facilitate responsible research evaluation by emphasizing contextual factors such as collaboration and research type. Experts highlight that this method combines quantitative and qualitative indicators for a fairer assessment of researcher contributions.

Clarivate Plc (NYSE: CLVT) announced its participation in the Morgan Stanley Technology, Media and Telecom Conference on March 4, 2021, at 9:30 AM Eastern Time. The presentation will be led by Jerre Stead, Executive Chairman and CEO, alongside Richard Hanks, CFO. A live webcast will be accessible on the Investor Relations section of the Clarivate website, with a replay available for 30 days following the event. Clarivate focuses on providing trusted information and insights to enhance innovation across various sectors.

Clarivate Plc (NYSE: CLVT) reported strong financial results for Q4 and the full year 2020. Q4 revenues reached $456 million, up 79%, while adjusted revenues increased to $471 million, up 85%. Adjusted net income surged 224% to $136 million, with adjusted EBITDA rising 137% to $200 million. Full-year revenues climbed to $1.254 billion, a 29% increase, but net loss improved by 50% to $106 million. The company experienced significant operational enhancements and reaffirmed its 2021 outlook, reflecting confidence in growth from recent acquisitions and strategic objectives.

Clarivate Plc (NYSE:CLVT) released a report highlighting the challenges businesses face regarding trademark value, protection, and infringements. Notably, 89% of brands experienced infringement in 2020, prompting 56% to change their brand names. High levels of management engagement are essential, as 89% of professionals noted missed revenue opportunities due to lack of engagement from C-suite executives. Despite challenges, trademark filings rose significantly, especially in the U.S. (up 35%). The report emphasizes the need for organizations to leverage technology to enhance trademark processes.

Clarivate Plc (NYSE:CLVT) has published a new report titled "Data categorization: understanding choices and outcomes", focusing on the organization of information within the global scientific community. The research, conducted in collaboration with Leiden University's CWTS, introduces a flexible, citation-based classification system that enhances data aggregation from the Web of Science citation network. With 10 macro topics, 326 meso topics, and 2,444 micro topics, this innovative approach aims to improve research data management practices and promote responsible use of research metrics.

Clarivate Plc (NYSE: CCC) announced a change of its ticker symbol to CLVT, effective February 1, 2021. This decision aims to enhance visibility among public investors and stakeholders, aligning the stock symbol with the company's name. CEO Jerre Stead highlighted the company's transformation and growth since its public listing in May 2019. Current stockholders do not need to take any action regarding this change, and the common stock will continue to trade on the NYSE with an unchanged CUSIP (G21810109).